Stockholm - Delayed Quote SEK

Karolinska Development AB (publ) (KDEV.ST)

Compare
1.2760 +0.0520 (+4.25%)
At close: October 18 at 5:22 PM GMT+2
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for KDEV.ST

Recent News: KDEV.ST

View More
Karolinska Development’s portfolio company Umecrine Cognition presents new preclinical Parkinson’s data on golexanolone at the scientific conference, INBC 2024

Karolinska Development’s portfolio company Umecrine Cognition presents new preclinical Parkinson’s data on golexanolone at the scientific conference, INBC 2024
Notice of Extraordinary General Meeting in Karolinska Development AB (publ)

Notice of Extraordinary General Meeting in Karolinska Development AB (publ)
Karolinska Development divests its holding in the Danish dermatology company Henlez

Karolinska Development divests its holding in the Danish dermatology company Henlez
Karolinska Development’s portfolio company AnaCardio reports progress in two clinical trials with its drug candidate AC01

Karolinska Development’s portfolio company AnaCardio reports progress in two clinical trials with its drug candidate AC01
Karolinska Developments portfolio company BOOST Pharma announces positive top-line results from a Phase 1/2 study with over 75% reduction of fracture rates in children with rare bone disease

Karolinska Developments portfolio company BOOST Pharma announces positive top-line results from a Phase 1/2 study with over 75% reduction of fracture rates in children with rare bone disease
Karolinska Development’s portfolio company Biosergen announces successful treatment of first patient in a clinical trial of BSG005

Karolinska Development’s portfolio company Biosergen announces successful treatment of first patient in a clinical trial of BSG005
Interim Report - January-June 2024

Interim Report - January-June 2024
Karolinska Development’s portfolio company PharmNovo receives EUR 17.5 million from the innovation program EIC Accelerator

Karolinska Development’s portfolio company PharmNovo receives EUR 17.5 million from the innovation program EIC Accelerator
Karolinska Development’s portfolio company Umecrine Cognition secures funding for continued clinical development of golexanolone

Karolinska Development’s portfolio company Umecrine Cognition secures funding for continued clinical development of golexanolone
Karolinska Development’s portfolio company Biosergen gets final approval to test lead candidate BSG005 in patients with invasive fungal infection

Karolinska Development’s portfolio company Biosergen gets final approval to test lead candidate BSG005 in patients with invasive fungal infection
Karolinska Development invests in BOOST Pharma, expanding its portfolio

Karolinska Development invests in BOOST Pharma, expanding its portfolio
View More

Related Tickers